Language

Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

New ALS Treatments Now Covered Under Provinces Publicly Funded Drug Plan

Released on September 1, 2023

People living with amyotrophic lateral sclerosis (ALS) may benefit from the addition of two medications to the Saskatchewan Drug Plan Formulary.

The Government of Saskatchewan is expanding treatment options for those living with ALS by listing Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) and the oral suspension of Radicava (edaravone) on the Saskatchewan Drug Plan Formulary. Effective September 1, eligible ALS patients who meet certain medical criteria may be considered for coverage of these medications under the Saskatchewan Drug Plan.

"Providing patients living with ALS additional treatment options is crucial, given the speed at which this disease progresses," Minister of Health Everett Hindley said. "Saskatchewan residents living with ALS know how debilitating this disease can be. Including these medications on the Saskatchewan Formulary gives patients access to potentially life-changing treatments."

ALS is a fatal neurodegenerative disease that affects around 3,000 Canadians. ALS rapidly causes patients to lose the ability to move and speak. As their condition progresses, ALS patients are significantly impacted in their ability to perform routine daily activities, such as feeding or grooming themselves. Ultimately, the disease leads to the loss of essential functions like swallowing and breathing. There is currently no cure for ALS, but medications such as Albrioza and Radicava may help slow the rate of disease progression.

"On behalf of the ALS Society of Saskatchewan we would like to thank the government for adding these to the Formulary as this will support those affected by ALS in the province," said Denis Simard, Executive Director of the ALS Society of Saskatchewan. "Anything that can help those living with ALS hold on to a quality of life for a longer period of time makes a big difference." 

Patients and families who think they or their family member may benefit from therapy with these medications are encouraged to speak with their physician.

-30-

For more information, contact:

Media Relations
Health
Regina
Phone: 306-787-4083
Email: media@health.gov.sk.ca

We need your feedback to improve saskatchewan.ca. Help us improve